Joel S. Parker, Ph.D.
Affiliations: | 2010 | Bioinformatics & Computational Biology | University of North Carolina, Chapel Hill, Chapel Hill, NC |
Area:
Bioinformatics, Genetics, OncologyGoogle:
"Joel Parker"Parents
Sign in to add mentor| Charles M. Perou | grad student | 2010 | UNC Chapel Hill | |
| (Clinical implementation of breast cancer genomics.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Conte B, Brasó-Maristany F, Hernández AR, et al. (2024) A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies. Ebiomedicine. 102: 105043 |
| Rediti M, Fernandez-Martinez A, Venet D, et al. (2023) Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature Communications. 14: 7053 |
| Parker JS, Mullins M, Cheang MCU, et al. (2023) Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 41: 4192-4199 |
| Tovey H, Sipos O, Parker JS, et al. (2023) Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF15 |
| Waks AG, Ogayo ER, Paré L, et al. (2023) Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab. Jama Oncology |
| Bueno-Muiño C, Echavarría I, López-Tarruella S, et al. (2023) Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. Jama Oncology |
| Prat A, Brasó-Maristany F, Martínez-Sáez O, et al. (2023) Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. Nature Communications. 14: 1157 |
| Price BA, Marron JS, Mose LE, et al. (2023) Translating transcriptomic findings from cancer model systems to humans through joint dimension reduction. Communications Biology. 6: 179 |
| Garcia-Recio S, Hinoue T, Wheeler GL, et al. (2022) Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nature Cancer |
| Brasó-Maristany F, Griguolo G, Chic N, et al. (2022) HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. Journal of the National Cancer Institute |